Related references
Note: Only part of the references are listed.Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer
Santosh Peddi et al.
BIOMACROMOLECULES (2020)
Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors
Sanford P. C. Hsu et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
mTOR complex 2 is an integrator of cancer metabolism and epigenetics
Kenta Masui et al.
CANCER LETTERS (2020)
Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
Kasun Wanigasooriya et al.
CANCERS (2020)
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
Dennis Heinzen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Rapamycin-loaded polysorbate 80-coated PLGA nanoparticles: Optimization of formulation variables and in vitro anti-glioma assessment
Oscar Escalona-Rayo et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2019)
Reversing the Tumor Target: Establishment of a Tumor Trap
Mathie Najberg et al.
FRONTIERS IN PHARMACOLOGY (2019)
mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma
Kenta Masui et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
Carmen Mecca et al.
DISEASE MARKERS (2018)
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2017)
Berunda Polypeptides: Multi-Headed Fusion Proteins Promote Subcutaneous Administration of Rapamycin to Breast Cancer In Vivo
Jugal P. Dhandhukia et al.
THERANOSTICS (2017)
Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo
Jugal P. Dhandhukia et al.
BIOCONJUGATE CHEMISTRY (2017)
Glioblastoma targeted therapy: updated approaches from recent biological insights
M. Touat et al.
ANNALS OF ONCOLOGY (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Local in vitro delivery of rapamycin from electrospun PEO/PDLLA nanofibers for glioblastoma treatment
Benlin Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Rapamycin/DiR loaded lipid-polyaniline nanoparticles for dual-modal imaging guided enhanced photothermal and antiangiogenic combination therapy
Jinping Wang et al.
JOURNAL OF CONTROLLED RELEASE (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Jenna Kahn et al.
NEURO-ONCOLOGY (2014)
Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo
Pu Shi et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets
Hua Mao et al.
CANCER INVESTIGATION (2012)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
Bipasha Mukherjee et al.
NEOPLASIA (2012)
Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
George J. Cerniglia et al.
MOLECULAR PHARMACOLOGY (2012)
Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
Arunkumar Anandharaj et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2011)
Poly(ethylene glycol)-Block-Poly(2-methyl-2-benzoxycarbonyl-propylene Carbonate) Micelles for Rapamycin Delivery: In Vitro Characterization and Biodistribution
Wenli Lu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats
Betty Tyler et al.
NEURO-ONCOLOGY (2011)
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2011)
Molecular targeting of glioblastoma: Drug discovery and therapies
Ren-Yuan Bai et al.
TRENDS IN MOLECULAR MEDICINE (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability
Archibald Paillard et al.
BIOMATERIALS (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma
Qi-Wen Fan et al.
SCIENCE SIGNALING (2010)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Mechanisms of Disease: the PI3K-Akt-PTEN signaling node - an intercept point for the control of angiogenesis in brain tumors
Robert C. Castellino et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance
Frederic Tremblay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis
Sherry A. Weppler et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Hypoxia-induced energy stress regulates mRNA translation and cell growth
LP Liu et al.
MOLECULAR CELL (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles
ML Forrest et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas
CB Knobbe et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2005)
Enhanced radiation damage of tumor vasculature by mTOR inhibitors
ET Shinohara et al.
ONCOGENE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Mechanisms of action of rapamycin in gliomas
AB Heimberger et al.
NEURO-ONCOLOGY (2005)
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
J Brugarolas et al.
GENES & DEVELOPMENT (2004)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
A novel phase inversion-based process for the preparation of lipid nanocarriers
B Heurtault et al.
PHARMACEUTICAL RESEARCH (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Solubilization of rapamycin
P Simamora et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2001)
Share Paper
